Abstract
Epstein–Barr (EB) virus is one of the five herpesviruses of man. Strong links between this agent and the chain of events causing two human cancers, endemic Burkitt's lymphoma and undifferentiated nasopharyngeal carcinoma, have long been evident (reviewed in ref. 1). Because of this, and because of the very high incidence of nasopharyngeal carcinoma in certain large populations2, it was suggested in 1976 that a vaccine should be developed against EB virus to prevent infection and thereby reduce tumour incidence amongst those at risk3. The virus-determined membrane antigen (MA) was proposed as immunogen3 because it was known to elicit naturally occurring virus-neutralizing antibodies in man4–7 and because analogous antigens had been shown to act as effective experimental vaccines for preventing the herpesvirus-induced lymphomas of Marek's disease in chickens8,9. Progress has been achieved in defining, quantifying and preparing MA molecules, and in enhancing their immunogenicity10; a sensitive assay for antibodies to MA has been elaborated11. Here we report that isolated cell membranes expressing MA, or purified MA glycoprotein of relative molecular mass (Mr) 340,000 (gp340), have been used to vaccinate cottontop tamarins (Saguinus oedipus oedipus), and that animals receiving either preparation were protected against the effects of a 100% tumour-inducing challenge dose of EB virus.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Epstein, M.A. & Achong, B.G. (eds) The Epstein-Barr Virus (Springer, Berlin, 1979).
Shanmugaratnam, K. Int. Rev. exp. Path. 10, 361–413 (1971).
Epstein, M.A. J. natn. Cancer Inst. 56, 697–700 (1976).
Pearson, G., Dewey, F., Klein, G., Henle, G. & Henle, W. J. natn. Cancer Inst. 45, 989–995 (1970).
Pearson, G., Henle, G. & Henle, W. J. natn. Cancer Inst. 46, 1243–1250 (1971).
Gergely, L., Klein, G. & Ernberg, I. Virology 45, 10–21 (1971).
De Schryver, A. et al. Int. J. Cancer. 13, 353–362 (1974).
Kaaden, O.R. & Dietzschold, B. J. gen. Virol. 25, 1–10 (1974).
Lesnick, F. & Ross, L.J.N. Int. J. Cancer 16, 153–163 (1975).
Epstein, M. A. Proc. R. Soc. B221, 1–20 (1984).
Randle, B.J. & Epstein, M.A. J. virol Meth. 9, 201–208 (1984).
Miller, G. in The Epstein-Barr Virus (eds Epstein, M. A. & Achong, B. G.) 351–372 (Springer, 1979).
Cleary, M.L. et al. Science 228, 722–724 (1985).
Kirkwood, J.K., Epstein, M.A. & Terlecki, A.J. Lab. Anim. 17, 35–41 (1983).
Kirkwood, J.K. Primates 24, 515–520 (1983).
Kirkwood, J.K., Epstein, M.A., Terlecki, A.J. & Underwood, S. J. Lab. Anim. (in the press).
North, J.R., Morgan, A.J., Thompson, J.L. & Epstein, M.A. J. virol. Meth. 5, 55–65 (1982).
Hudewentz, J., Bornkamm, G.W. & zur Hausen, H. Virology 100, 175–178 (1980).
Crumpton, M.J. & Snary, D., Topics molec. Immun. 3, 27–56 (1974).
Moss, D.J. & Pope, J.H. J. gen. Virol. 17, 233–236 (1972).
Morgan, A.J., North, J.R. & Epstein, M.A. J. gen. Virol. 64, 455–460 (1983).
North, J.R., Morgan, A.J., Thompson, J.L. & Epstein, M.A. Proc. natn. Acad. Sei. 79, 7504–7508 (1982).
Morgan, A.J., Epstein, M.A. & North, J.R. J. med. Virol 13, 281–292 (1984).
Epstein, M.A., Randle, B.J., Finerty, S. & Kirkwood, J. K. Clin. exp. Immun. (in the press).
Morgan, A.J., Smith, A.R., Barker, R.N. & Epstein, M.A. J. gen. Virol. 65, 397–404 (1984).
Hummel, M., Thorley-Lawson, D.A. & Kieff, E. J. Virol. 49, 413–417 (1984).
Biggin, M., Farrell, P.J. & Barrell, B.G. EMBO J. 3, 1083–1090 (1984).
Morein, B., Sundquist, B., Höglund, S., Dalsgaard, K. & Osterhaus, A. Nature 308, 457–460 (1984).
Smith, G.L., Mackett, M. & Moss, B. Nature 302, 490–495 (1983).
Moss, B., Smith, G.L., Gerin, J.L. & Purcell, R.H. Nature 311, 67–69 (1984).
Mackett, M., Yilma, T., Rose, J.K. & Moss, B. Science 227, 433–435 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Epstein, M., Morgan, A., Finerty, S. et al. Protection of cottontop tamarins against Epstein–Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 318, 287–289 (1985). https://doi.org/10.1038/318287a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/318287a0
This article is cited by
-
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications
Nature Reviews Neurology (2023)
-
Urgency and necessity of Epstein-Barr virus prophylactic vaccines
npj Vaccines (2022)
-
Epstein–barr virus vaccines
Clinical & Translational Immunology (2015)
-
Modeling EBV infection and pathogenesis in new-generation humanized mice
Experimental & Molecular Medicine (2015)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.